Skip to main content

Table 5 Follow-up evaluations

From: Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

  Before Treatment Year 1a Year 2–5a
History and Physical X 3, 6, 9, 12 mo 18 mo, 24 mo, then annually
Assessment by Respirology/Pulmonology X At least every 6 months At least annually
Central review of ILD diagnosis X   
PET/CT X   
Brain MRI If symptoms (see Pre-treatment Evaluation)   
Mediastinal staging Optional (see Pre-treatment Evaluation)   
HRCT chest X 3, 6, 12 mo 18 mo, 24 mo, then annually
PFTsb X 6, 12 mo 18 mo, 24 mo, then annually
Toxicity Scoring X 3, 6, 9, 12 mo 18 mo, 24 mo, then annually
FACT-L, EQ-5D-5L QOL scoring and cough severity scale X 3, 6, 9, 12 mo 18 mo, 24 mo, then annually
  1. aAll times are measured from end of radiation
  2. bTo avoid duplication of PFTs, if the patient is having PFTs done by other physicians (e.g. respirologists), the PFTs must only be +/− 2 months of the dates stated above to be acceptable